Actively Recruiting
Phase 2 Study of BMS-986340 Combined With Nivolumab, Gemcitabine, and Nab-Paclitaxel for First Treatment of Advanced Pancreatic Adenocarcinoma
Led by Mayo Clinic · Updated on 2026-06-09
43
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This trial studies patients with metastatic or recurrent pancreatic adenocarcinoma to evaluate the safety, side effects, and best dose of BMS-986340 combined with nivolumab, gemcitabine, and nab-paclitaxel. BMS-986340 is a monoclonal antibody that may affect tumor growth and spread. Immunotherapy with monoclonal antibodies like nivolumab may help the immune system attack tumors, while gemcitabine and nab-paclitaxel are chemotherapy drugs that may kill tumor cells. This is a Phase II trial focused on treatment effectiveness and safety.
CONDITIONS
Brief Title
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Research Team
C
Clinical Trials Referral Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
